Anda di sini
Formulari Ubat KKM (FUKKM)
| # | Generic Name | MDC | Category | Indications | Pres. Restrictions | Dosage |
|---|---|---|---|---|---|---|
| 1111 | Nicotine 4mg Gum | N07BA01000M9902XX | A/KK | For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit. | Smokes ≤ 20 sticks/day, chew 2mg gum. Smokes ≥ 20 sticks/day, chew 4 mg gum. (MAX 24 pieces /day for up to 12 week.) | |
| 1112 | Nicotine 7mg/24hr Transdermal Patch | N07BA01000M7001XX | A/KK | For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit. | The patch should be apply to an intact area of the skin upon waking up in the morning and removed at 24hrs. Smokers of >10 cigarettes/day: 21 mg/day for 6 wk, then 14 mg/day for 2 wk; finish w/ 7 mg/day for 2 wk. Smokers of ≤10 cigarettes/day: 14 mg/day for 6 wk, then 7 mg/day for 2 wk. | |
| 1113 | Nicotinic Acid 50 mg Tablet | A11HA01000T1001XX | B | For prophylaxis and treatment of Vitamin B3 deficiency | Prophylactic: 15 - 30 mg daily. Therapeutic: 50 - 250 mg daily. Maximum single dose: 200 mg. Maximum dose in 24 hours: 800 mg | |
| 1114 | Nicotinic Acid 500 mg Tablet | C10AD02000T1001XX | B | Hyperlipidaemia | 100 - 200 mg 3 times daily, gradually increased over 2 - 4 weeks to 1 - 2 g 3 times daily with or after meals. CHILD: 100 - 250 mg/day in 3 divided doses with meals, increase 100 mg/day weekly or 250 mg/day every 2 - 3 weeks as tolerated. Maximum: 10 mg/kg/day | |
| 1115 | Nifedipine 10 mg Tablet | C08CA05000T1001XX | B | Hypertension | Initial dose of 10 mg twice daily. Usual range 10 - 30 mg 3 times daily. Maximum: 120 - 180 mg per day. Elderly: Dose reduction may be necessary. | |
| 1116 | Nilotinib 150mg capsule | L01XE08110T1001XX | A* | For the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in the chronic phase (CP). | 300mg twice daily. Dose adjustments or modifications:For neutropenia & thrombocytopenia | |
| 1117 | Nilotinib 200 mg Capsule | L01XE08110C1001XX | A* | Treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in adults who: i) Failed imatinib ie no cytogenic response and no haematological response by 12 months ii) Have molecular resistance to Imatinib as shown by molecular mutation studies iii) Are intolerant to Imatinib | 400 mg twice daily, 12 hours apart. No food should be taken two hours before and 1 hour after taking the dose | |
| 1118 | Nimodipine 10 mg/50 ml Infusion Solution | C08CA06000P9901XX | A* | Prophylaxis & treatment of ischaemic neurological deficits caused by cerebral vasospasm following subarachnoid haemorrhage of aneurysmal origin | IV infusion of 1 mg/hour for a period of 2 hours (about 15 mcg/kg/hour). IV therapy should be started no later than 4 days after haemorrhage & continue for up to 10 - 14 days | |
| 1119 | Nimodipine 30 mg Tablet | C08CA06000T1001XX | A* | Prophylaxis & treatment of ischaemic neurological deficits caused by cerebral vasospasm following subarachnoid haemorrhage of aneurysmal origin | 360 mg daily in divided doses for 7 days | |
| 1120 | Nintedanib 100mg Capsule | L01XE31-189-C40-01-XXX | A* | i) For the treatment of Idiopathic Pulmonary Fibrosis (IPF) in adults ii) Indicated in adults for the treatment of other chronic fibrosing lung disease (ILDs) with a progressive phenotype | For indication (ii): • FVC at least 40% of predicted value, and • DLCO 30% to 89% of predicted value • To be prescribed by Consultant Respiratory Physician and Rheumatologist only | i) The recommended dose is 150 mg twice daily administered approximately 12 hours apart. The 100 mg twice daily dose is only recommended to be used in patients who do not tolerate the 150 mg twice daily dose. ii) 150mg twice a day |
| 1121 | Nintedanib 150mg Capsule | L01XE31-189-C40-02-XXX | A* | i) For the treatment of Idiopathic Pulmonary Fibrosis (IPF) in adults ii) Indicated in adults for the treatment of other chronic fibrosing lung disease (ILDs) with a progressive phenotype | For indication (ii): • FVC at least 40% of predicted value, and • DLCO 30% to 89% of predicted value • To be prescribed by Consultant Respiratory Physician and Rheumatologist only | i) The recommended dose is 150 mg twice daily administered approximately 12 hours apart. The 100 mg twice daily dose is only recommended to be used in patients who do not tolerate the 150 mg twice daily dose. ii) 150mg twice a day |
| 1122 | Nirsevimab 100 mg/mL Solution for Injection in Pre-filled Syringe | J06BD08-000-P50-01-xxx | A* | Indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in: i. Neonates and infants during their first RSV season. ii. Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. | i. Infants at high risk, including those with: • Prematurity: born at ≤32 weeks gestational age. • Bronchopulmonary dysplasia (BPD) or chronic lung disease (CLD) • Congenital heart disease (CHD) • Immunocompromised (immunodeficiency) ii. Not indicated for neonates and young infants <6 months of age whose mothers received an RSV vaccine during the third trimester at least 14 days before delivery, as maternal vaccination is expected to provide passive protection against severe RSV disease. iii. To be prescribed by Neonatologists, Paediatric Infectious Disease and Paediatric Cardiologists only | First RSV season: i. Body weight <5kg: 50 mg intramuscularly ii. Body weight ≥5kg: 100 mg intramuscularly Second RSV season: 200 mg intramuscularly Refer to package insert for full details on dose for specific population or condition |
| 1123 | Nirsevimab 50 mg/0.5 mL Solution for Injection in Pre-filled Syringe | J06BD08-000-P50-02-xxx | A* | Indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in: i. Neonates and infants during their first RSV season. ii. Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. | i. Infants at high risk, including those with: • Prematurity: born at ≤32 weeks gestational age. • Bronchopulmonary dysplasia (BPD) or chronic lung disease (CLD) • Congenital heart disease (CHD) • Immunocompromised (immunodeficiency) ii. Not indicated for neonates and young infants <6 months of age whose mothers received an RSV vaccine during the third trimester at least 14 days before delivery, as maternal vaccination is expected to provide passive protection against severe RSV disease. iii. To be prescribed by Neonatologists, Paediatric Infectious Disease and Paediatric Cardiologists only | First RSV season: i. Body weight <5kg: 50 mg intramuscularly ii. Body weight ≥5kg: 100 mg intramuscularly Second RSV season: 200 mg intramuscularly Refer to package insert for full details on dose for specific population or condition |
| 1124 | Nitrazepam 5 mg Tablet | N05CD02000T1001XX | B | Epilepsy (infantile spasms) | 5 - 10 mg at bedtime. ELDERLY or debilitated 2.5 - 5 mg. CHILD not recommended. Increasing slowly according to response | |
| 1125 | Nitrofurantoin 100mg Tablet | J01XE01-000-T10-02-XXX | B | Uncomplicated lower urinary tract infections | None | Acute uncomplicated urinary tract infections Adult: 50-100 mg 4 times daily for 7 days. Dual-release preparation: 100 mg bid. Child: >3 mth and older children: 3 mg/kg daily in 4 divided doses. Prophylaxis of uncomplicated urinary tract infections Adult: 50-100 mg at bedtime. Child: >3 mth and older children: 1 mg/kg once daily. |
| 1126 | Nivolumab 10mg/mL Concentrate for Solution for Infusion | L01XC17-000-P33-01-xxx | A* | As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults. | None | 3 mg/kg administered intravenously over 30 minutes every 2 weeks. |
| 1127 | Noradrenaline Acid Tartrate (Norepinephrine Bitartrate) 1 mg/ml Injection | C01CA03-123-P30-01-XXX | A, A/KK | Category A: i) For blood pressure control in certain acute hypotensive states (e.g.pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions). ii) As an adjunct in the treatment of cardiac arrest and profound hypotension Category A/KK: Septic shock and shock where peripheral vascular resistance is low | Category A: None Category A/KK: Use only for emergency cases in health clinic with Medical Officers (MO) upon consultation with Family Medicine Specialist (FMS) | Infuse and titrate to desired pressure response. Range: 0.05 - 0.5 mcg/kg/minute |
| 1128 | Norethisterone 0.35 mg Tablet | G03AC01000T1001XX | C+ | Contraception | 1 tablet daily starting on the first day of the menstrual bleeding | |
| 1129 | Norethisterone Enanthate 200 mg/ml Injection | G03AC01257P3001XX | B | Contraception | By deep IM injection only. First injection is within first 5 days of the cycle. The next 3 injections are given at 8 weeks interval after which the injection interval should be extended to 12 weeks | |
| 1130 | Nystatin 100,000 units/g Cream | D01AA01-000-G10-01-XXX | C | Prevention and treatment of cutaneous infections caused by Candida albicans | None | Apply liberally to affected area twice daily or as required. After lesion has disappeared continue treatment for 10 days to prevent relapses. Nail infection: Cut nails as short as possible. Apply cream once daily until growth of new nail has set in |
| 1131 | Nystatin 100,000units/ml Suspension | A07AA02-000-L80-01-XXX | B | Treatment of candidal infection of the oral cavity | None | ADULT and CHILDREN One to six ml (100,000 to 600,000 units) four times daily after food INFANTS One ml (equivalent to 100,000 units) four times daily after food. Dosing is individualised and according to product insert/protocol. |
| 1132 | Nystatin 500,000 units Tablet | A07AA02-000-T10-01-XXX | B | Prevention and treatment of candidiasis of the skin and mucous membranes, protection against candidas overgrowth during antimicrobial /corticosteroid therapy and as selective decontamination regimens | None | ADULT: 500,000 -1,000,000 units 6 hourly, according to severity of infections. CHILD: 100,000-500,000 units 6 hourly |
| 1133 | Octreotide 0.05mg/ml Injection | H01CB02-122-P30-02-XXX | A | i) Acromegaly treatment in patients in whom surgery or radiotherapy is inappropriate or ineffective- based on level of growth hormone and high IGF-1 and residual pituitary tumor ii) Relief of symptoms associated with functional gastro-entero-pancreatic (GEP) endocrine tumors: • Carcinoid tumors with features of the carcinoid syndrome. • VIPomas, Glucagonomas • Gastrinomas/Zollinger-Ellison syndrome • Insulinomas • GRFomas. iii) Prevention of complications following pancreatic surgery iv) Emergency management of bleeding gastro-eosophageal varices in patients with cirrhosis | None | i) Initially 0.05-0.1mg SC every 8 or 12 hours. Optimal daily dose is 0.3mg, not to exceed maximum dose of 1.5mg/day. ii) Initially 0.05 mg once or twice daily, gradually increase to 0.1-0.2mg 3 times daily. Higher doses may be required in exceptional circumstances. iii) 0.1 mg 3 times daily for 7 consecutive days, starting on the day of operation, at least 1 hour before laparotomy iv) ADULT: 50mcg bolus, followed by continuous infusion of 25-50mcg/hour for 2-5 days. CHILD: IV 1-5 mcg/kg/hour The dosing is individualized according to product insert / protocol |
| 1134 | Octreotide 0.1mg/ml Injection | H01CB02-122-P30-01-XXX | A | i) Acromegaly treatment in patients in whom surgery or radiotherapy is inappropriate or ineffective- based on level of growth hormone and high IGF-1 and residual pituitary tumor ii) Relief of symptoms associated with functional gastro-entero-pancreatic (GEP) endocrine tumors: • Carcinoid tumors with features of the carcinoid syndrome. • VIPomas, Glucagonomas • Gastrinomas/Zollinger-Ellison syndrome • Insulinomas • GRFomas. iii) Prevention of complications following pancreatic surgery iv) Emergency management of bleeding gastro-eosophageal varices in patients with cirrhosis | None | i) Initially 0.05-0.1mg SC every 8 or 12 hours. Optimal daily dose is 0.3mg, not to exceed maximum dose of 1.5mg/day. ii) Initially 0.05 mg once or twice daily, gradually increase to 0.1-0.2mg 3 times daily. Higher doses may be required in exceptional circumstances. iii) 0.1 mg 3 times daily for 7 consecutive days, starting on the day of operation, at least 1 hour before laparotomy iv) ADULT: 50mcg bolus, followed by continuous infusion of 25-50mcg/hour for 2-5 days. CHILD: IV 1-5 mcg/kg/hour The dosing is individualized according to product insert / protocol |
| 1135 | Octreotide Acetate 20mg Injection | H01CB02-122-P20-01-XXX | A* | i) Acromegaly treatment in patients in whom surgery or radiotherapy is inappropriate or ineffective- based on level of growth hormone and high IGF-1 and residual pituitary tumor. ii)Treatment of patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumors: • Carcinoid tumors with features of the carcinoid syndrome. • VIPomas, Glucagonomas • Gastrinomas/Zollinger-Ellison syndrome. • Insulinomas, GRFomas. iii) Treatment of patients with advanced neuroendocrine tumors of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded. | None | 10 - 30 mg every 4 weeks as deep intragluteal injection |
| 1136 | Octreotide Acetate 30mg Injection | H01CB02-122-P20-02-XXX | A* | i) Acromegaly treatment in patients in whom surgery or radiotherapy is inappropriate or ineffective- based on level of growth hormone and high IGF-1 and residual pituitary tumor. ii) Treatment of patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumors: • Carcinoid tumors with features of the carcinoid syndrome. • VIPomas, Glucagonomas • Gastrinomas/Zollinger-Ellison syndrome. • Insulinomas, GRFomas. iii) Treatment of patients with advanced neuroendocrine tumors of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded. | None | 10 - 30 mg every 4 weeks as deep intragluteal injection |
| 1137 | Ofatumumab 20mg/0.4mL Injection in Prefilled Syringe | L01XC10-000-P50-01-xxx | A* | Indicated for the treatment of relapsing form of multiple sclerosis (RMS), to include relapsing-remitting disease and active secondary progressive disease, in adults. | To be prescribed by Consultant Neurologist only | The recommended dose is 20 mg at weeks 0,1 and 2 followed by 20 mg once monthly starting at week 4, administered as subcutaneous injection. |
| 1138 | Ofloxacin 0.3% Otic Solution | S02AA00-000-D10-01-XXX | A/KK | i. Acute otitis media with tympanostomy tubes ii. Chronic suppurative otitis media with perforated tympanic membranes and iii. Otitis externa | None | CHILD: 1 - 12 years: 5 drops twice daily for 10 days. ADULT and CHILD over 12 years: 6 - 10 drops twice daily and remain in the ear about 10 minutes |
| 1139 | Ofloxacin 100 mg Tablet | J01MA01000T1001XX | A | i) As second-line treatment of leprosy ii) As second-line treatment for tuberculosis and multidrug resistant tuberculosis (MDR-TB) iii) Sequential therapy for UTI and pyelonephritis | i) 400 mg/day ii) 400 mg twice daily iii) 200 mg twice daily | |
| 1140 | Ofloxacin 200 mg Injection | J01MA01000P4001XX | A | Sequential therapy for UTI and pyelonephritis | 200 mg IV twice daily for 3 - 5 days followed with 200 mg tablet twice daily for 3 - 5 days as maintenance dose (if necessary) |